ClinicalTrials.gg
Enrolling by invitationNCT07664423Updated Nov 20, 2026

BRIDGES: An HIV Doula Program

An interventional study of Doula Support Intervention in Pregnant HIV Positive Women, sponsored by University of Miami. Enrolling by invitation at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by University of Miami · Not applicable, Interventional, and Prevention

How we know

Updated Nov 20, 2026Now Enrolling by invitationStart date moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Study summary

The purpose of BRIDGES (BReast and Infant feeding Doulas to address Gaps in Education and Support) is to develop, test and disseminate an HIV Doula education and support program to improve maternal/child health outcomes and reduce perinatal transmission.

02

Conditions studied

  • Pregnant HIV Positive Women

Keywords

  • Doula
  • Infant Feeding
  • HIV
03

In context

Lead sponsor

University of Miami is the lead sponsor of 843 studies on the registry; 166 are open to participants now.

Of its 115 completed or terminated interventional studies of FDA-regulated products, 97 (84%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pregnant and postnatal women, followed at the institutional clinic for women with
  • > = 18 years old, with an HIV diagnosis
  • Pregnant or postnatal
  • Reside in South Florida
  • Able to communicate at the 6th grade level in English, Spanish or Haitian Creole.

Exclusion criteria

Exclusion Criteria:

  • Under 18
  • Not able to read/write English, Spanish or Haitian Creole at the 6th grade level
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (estimated)

Study arms

  • Experimental
    Doula Support Intervention

    Pregnant women with HIV will receive a structured doula support intervention in addition to routine clinical care. Participants will be paired with a trained study doula who provides prenatal and postnatal support from pregnancy through 12 weeks postpartum.

    Behavioral: Doula Support Intervention

Interventions

  • BehavioralDoula Support Intervention

    A trained study doula provides behavioral support, including prenatal education, adherence support, and lactation counseling, from pregnancy through 12 weeks postpartum.

06

What researchers measure

Primary outcomes

  1. Feasibility of Enrollment into the HIV Doula Program

    Percentage of eligible participants approached for participation who enroll in the HIV Doula Program

    Time frame: Baseline through 6 months

  2. Acceptability of the HIV Doula Program (Participant Retention)

    Percentage of enrolled participants who are retained at each protocol defined study visit during the 6-month follow-up period.

    Time frame: Baseline through 6 months

  3. Uptake of the HIV Doula Program by Preferred Language

    Percentage of eligible individuals approached for participation who enroll in the HIV Doula Program, stratified by participant reported preferred language.

    Time frame: Baseline through 6 months

Secondary outcomes

  1. Participants with Undetectable HIV Viral Load (<20 copies/mL)

    Percentage of participants with undetectable HIV viral load, defined as \<20 copies/mL. Data is obtained from clinically collected tests as part of routine care and abstracted from participants' medical records.

    Time frame: 9 months

  2. Initiated Breastfeeding After Birth

    Percentage of participants who initiated breastfeeding after babies' birth.

    Time frame: 6 months

07

Study locations

1 site
08

References and documents

Publications

  • Mpanu-Mpanu R, Francis M, Garcia KN, Duthely LM. BRIDGES: a patient-centered, community-informed HIV doula program that supports infant feeding choice among Hispanic and Caribbean families: a study protocol. Front Reprod Health. 2026 Aug 28;8:1896729. doi: 10.3389/frph.2026.1896729. eCollection 2026. PubMed 42729342 ↗

Individual participant data

Plan to share: No — Due to confidentiality

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Aug 2026 (actual). Primary completion is estimated for May 2027, 8 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 20, 2026: start Sep 2026 → Aug 2026, primary completion Sep 2027 → May 2027 and completion Sep 2027 → May 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 10, 2026
First posted
Jun 24, 2026
StartActual
Aug 27, 2026was Sep 2026
Primary completionEst.
May 15, 2027was Sep 2027
CompletionEst.
May 31, 2027was Sep 2027
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Enrolling by invitation
changed Nov 20, 2026
Start date
Sep 2026→Aug 27, 2026 (actual)
Nov 20, 2026
Primary completion
Sep 2027→May 15, 2027
Nov 20, 2026
Study completion
Sep 2027→May 31, 2027
Nov 20, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 42729342 ↗
Nov 20, 2026
Contact
No study contact listed any more: removed c•••@med.miami.edu · •••5800
Nov 20, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • University of Miami School of Medicine · Miami, United StatesContact removed m•••@miami.edu · •••5800Contact removed (no phone or email listed)
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    Not yet recruiting→Enrolling by invitation
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 42729342 ↗
    Start date Sep 2026→Aug 27, 2026 (now actual)
    Primary completion Sep 2027→May 15, 2027
    Study completion Sep 2027→May 31, 2027
    Contact No study contact listed any more: removed c•••@med.miami.edu · •••5800
    Site contacts Changed at 1 site. See the sites
    Show the site
    • University of Miami School of Medicine · Miami, United StatesContact removed m•••@miami.edu · •••5800Contact removed (no phone or email listed)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07664423
Responsible party
Lunthita M. Duthely (Research Associate Professor, University of Miami) — Principal investigator
First posted
Jun 24, 2026
Start date
Aug 27, 2026
Primary completion
May 15, 2027 (estimated)
Completion
May 31, 2027 (estimated)
Last update
Nov 20, 2026

Study contacts

Lunthita M Duthely, Ed.D.
principal investigator · University of Miami

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion